New PET tracer could spot hidden cancers

NCT ID NCT07593209

Recruiting now Diagnosis Sponsor: First Hospital of China Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new radioactive imaging agent called 68Ga-DOTA-EphA2 to help see certain proteins on cancer cells during PET/CT scans. The goal is to improve how doctors detect and monitor malignant tumors. About 30 adults with suspected or confirmed cancer will receive the agent and then have a scan to see where it goes in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-DOTA-EphA2 (a radioactive imaging agent)
What this could lead to: If successful, this could provide a new way to detect and monitor certain cancers more accurately using PET/CT scans.
What could go wrong: This is a small, early-phase study focused on imaging, not treatment. The agent may not work well for all tumor types, and there is a risk of side effects from the radioactive tracer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMOR

Contacts and locations

Locations

PET
RECRUITING

Shenyang, Liaoning, 110001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.